Frequency and Prognostic Impact of ALK Amplifications and Mutations in High-Risk Neuroblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
J. Clin. Oncol 2021 Jun 11;[EPub Ahead of Print], A Bellini, U Pötschger, V Bernard, E Lapouble, S Baulande, PF Ambros, N Auger, K Beiske, M Bernkopf, DR Betts, J Bhalshankar, N Bown, K de Preter, N Clément, V Combaret, J Font de Mora, SL George, I Jiménez, M Jeison, B Marques, T Martinsson, K Mazzocco, M Morini, A Mühlethaler-Mottet, R Noguera, G Pierron, M Rossing, S Taschner-Mandl, N Van Roy, A Vicha, L Chesler, W Balwierz, V Castel, M Elliott, P Kogner, G Laureys, R Luksch, J Malis, M Popovic-Beck, S Ash, O Delattre, D Valteau-Couanet, DA Tweddle, R Ladenstein, G SchleiermacherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.